Molecular Imaging Market Size, Share, & Trends Analysis Report By Modality (Molecular Ultrasound Imaging, Positron Emission Tomography), By Application (Cardiovascular, Neurology), By End Use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business days
Molecular Imaging Market Growth & Trends
The global molecular imaging market size is estimated t%li%reach USD 11.4 billion by 2030, expanding at a CAGR of 4.6% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc. The major factors contributing t%li%market growth include technological advancements, increase in prevalence of cancer, and rising investment in R&D. For instance, according t%li%the International Agency for Research on Cancer, approximately 19,976,499 new cancer cases and 9,743,832 cancer-related deaths were reported globally in 2022.
The growing prevalence of chronic disorders such as cancer, cardiovascular diseases, and neurological conditions necessitates effective diagnostic tools, which are expected t%li%significantly contribute t%li%the growth of the molecular imaging market. Molecular imaging devices such as PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and Nuclear Magnetic Resonance (NMR) Spectrometer are particularly efficient in this regard. These advanced technologies provide detailed insights int%li%the metabolic processes, molecular activities, and structural changes associated with various diseases. They enable healthcare professionals t%li%visualize and assess the extent and characteristics of tumors, cardiac function, and neurological abnormalities with high precision and accuracy.
Moreover, molecular imaging facilitates early detection of diseases, even at subclinical stages, allowing for timely intervention and personalized treatment planning. This proactive approach not only improves patient outcomes but als%li%reduces healthcare costs associated with advanced disease stages and complications.
Strategic initiatives undertaken by major market players, including mergers and acquisitions, product launches, regulatory approvals, partnerships, collaborations, and research and development (R&D) activities, play a crucial role in driving the growth of the molecular imaging market. For instance, in January 2024, Bruker Corporation successfully installed a state-of-the-art 1.2 Gigahertz (GHz) NMR system at The Ohi%li%State University's National Gateway Ultrahigh Field NMR Center. This GHz-class NMR system represents a significant advancement in nuclear magnetic resonance (NMR) spectroscopy, aiming t%li%revolutionize research in life sciences and materials science.
Molecular Imaging Market Report Highlights
Molecular Imaging Market Growth & Trends
The global molecular imaging market size is estimated t%li%reach USD 11.4 billion by 2030, expanding at a CAGR of 4.6% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc. The major factors contributing t%li%market growth include technological advancements, increase in prevalence of cancer, and rising investment in R&D. For instance, according t%li%the International Agency for Research on Cancer, approximately 19,976,499 new cancer cases and 9,743,832 cancer-related deaths were reported globally in 2022.
The growing prevalence of chronic disorders such as cancer, cardiovascular diseases, and neurological conditions necessitates effective diagnostic tools, which are expected t%li%significantly contribute t%li%the growth of the molecular imaging market. Molecular imaging devices such as PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and Nuclear Magnetic Resonance (NMR) Spectrometer are particularly efficient in this regard. These advanced technologies provide detailed insights int%li%the metabolic processes, molecular activities, and structural changes associated with various diseases. They enable healthcare professionals t%li%visualize and assess the extent and characteristics of tumors, cardiac function, and neurological abnormalities with high precision and accuracy.
Moreover, molecular imaging facilitates early detection of diseases, even at subclinical stages, allowing for timely intervention and personalized treatment planning. This proactive approach not only improves patient outcomes but als%li%reduces healthcare costs associated with advanced disease stages and complications.
Strategic initiatives undertaken by major market players, including mergers and acquisitions, product launches, regulatory approvals, partnerships, collaborations, and research and development (R&D) activities, play a crucial role in driving the growth of the molecular imaging market. For instance, in January 2024, Bruker Corporation successfully installed a state-of-the-art 1.2 Gigahertz (GHz) NMR system at The Ohi%li%State University's National Gateway Ultrahigh Field NMR Center. This GHz-class NMR system represents a significant advancement in nuclear magnetic resonance (NMR) spectroscopy, aiming t%li%revolutionize research in life sciences and materials science.
Molecular Imaging Market Report Highlights
- Based on the modality segment, the Single Photon Emission Computed Tomography (SPECT) segment dominated by capturing a share of 43.3% in 2024
- The Nuclear Magnetic Resonance (NMR) spectrometer segment is anticipated t%li%be the fastest-growing segment, with a CAGR of 8.8% from 2025 t%li%2030.
- Based on application, Oncology segment accounted for the largest market share in 2024 due t%li%the rising global cancer burden and the growing demand for advanced diagnostic solutions.
- Based on end use, Hospitals segment held the largest market share in 2024 due t%li%the increasing adoption of advanced imaging technologies in clinical settings.
- The diagnostic imaging centers segment is projected t%li%be the fastest-growing segment over the forecast period, driven by the ability t%li%offer high-quality, specialized imaging procedures with efficient turnaround times compared t%li%larger hospitals.
- North America dominated the market with a share of 41. 4% in 2024.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Modality
1.2.2. Application
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Modality Outlook
2.2.2. Application Outlook
2.2.3. End Use Outlook
2.2.4. Regional Outlook
2.3. Competitive Insights
CHAPTER 3. MOLECULAR IMAGING MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Molecular Imaging Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
CHAPTER 4. MOLECULAR IMAGING MARKET: MODALITY ESTIMATES & TREND ANALYSIS
4.1. Modality Segment Dashboard
4.2. Molecular Imaging Market: Modality Movement Analysis
4.3. Global Molecular Imaging Market Size & Trend Analysis, by Modality, 2018 to 2030 (USD Million)
4.4. Molecular Ultrasound Imaging
4.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.5. Positron Emission Tomography (PET)
4.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.6. Single Photon Emission Computed Tomography (SPECT)
4.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.7. Nuclear Magnetic Resonance (NMR) Spectrometer
4.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. MOLECULAR IMAGING MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Application Segment Dashboard
5.2. Molecular Imaging Market: Application Movement Analysis
5.3. Global Molecular Imaging Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Cardiovascular
5.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.5. Neurology
5.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.6. Oncology
5.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.7. Respiratory
5.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.8. Gastrointestinal
5.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. MOLECULAR IMAGING MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. End Use Segment Dashboard
6.2. Molecular Imaging Market: End Use Movement Analysis
6.3. Global Molecular Imaging Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
6.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5. Diagnostic Imaging Centers
6.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6. Research Institutes
6.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 7. MOLECULAR IMAGING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Molecular Imaging Market by Region: Key Takeaways
7.4. North America
7.4.1. U.S.
7.4.1.1. Key Country Dynamics
7.4.1.2. Regulatory Framework/ Reimbursement Structure
7.4.1.3. Competitive Scenario
7.4.1.4. U.S. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.4.2. Canada
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework/ Reimbursement Structure
7.4.2.3. Competitive Scenario
7.4.2.4. Canada Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.4.3. Mexico
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework/ Reimbursement Structure
7.4.3.3. Competitive Scenario
7.4.3.4. Mexico Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. U.K.
7.5.1.1. Key Country Dynamics
7.5.1.2. Regulatory Framework/ Reimbursement Structure
7.5.1.3. Competitive Scenario
7.5.1.4. U.K. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework/ Reimbursement Structure
7.5.2.3. Competitive Scenario
7.5.2.4. Germany Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.3. France
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework/ Reimbursement Structure
7.5.3.3. Competitive Scenario
7.5.3.4. France Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.4. Italy
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework/ Reimbursement Structure
7.5.4.3. Competitive Scenario
7.5.4.4. Italy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.5. Spain
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework/ Reimbursement Structure
7.5.5.3. Competitive Scenario
7.5.5.4. Spain Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.6. Denmark
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework/ Reimbursement Structure
7.5.6.3. Competitive Scenario
7.5.6.4. Denmark Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.7. Sweden
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework/ Reimbursement Structure
7.5.7.3. Competitive Scenario
7.5.7.4. Sweden Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.8. Norway
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework/ Reimbursement Structure
7.5.8.3. Competitive Scenario
7.5.8.4. Norway Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Regulatory Framework/ Reimbursement Structure
7.6.1.3. Competitive Scenario
7.6.1.4. Japan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework/ Reimbursement Structure
7.6.2.3. Competitive Scenario
7.6.2.4. China Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6.3. India
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework/ Reimbursement Structure
7.6.3.3. Competitive Scenario
7.6.3.4. India Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6.4. Australia
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework/ Reimbursement Structure
7.6.4.3. Competitive Scenario
7.6.4.4. Australia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework/ Reimbursement Structure
7.6.5.3. Competitive Scenario
7.6.5.4. South Korea Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework/ Reimbursement Structure
7.6.6.3. Competitive Scenario
7.6.6.4. Thailand Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework/ Reimbursement Structure
7.7.2.3. Competitive Scenario
7.7.2.4. Brazil Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework/ Reimbursement Structure
7.7.3.3. Competitive Scenario
7.7.3.4. Argentina Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework/ Reimbursement Structure
7.8.2.3. Competitive Scenario
7.8.2.4. South Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework/ Reimbursement Structure
7.8.3.3. Competitive Scenario
7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework/ Reimbursement Structure
7.8.4.3. Competitive Scenario
7.8.4.4. UAE Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework/ Reimbursement Structure
7.8.5.3. Competitive Scenario
7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company/ Competition Categorization
8.3. Vendor Landscape
8.3.1. Key Company Heat Map Analysis, 2024
8.4. Company Profiles
8.4.1. Bruker
8.4.1.1. Company Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. GE HealthCare
8.4.2.1. Company Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Siemens Healthineers AG
8.4.3.1. Company Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Koninklijke Philips N.V.
8.4.4.1. Company Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Canon Medical Systems Corporation
8.4.5.1. Company Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Mediso Ltd.
8.4.6.1. Company Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Cubresa Inc.
8.4.7.1. Company Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Shimadzu Corporation
8.4.8.1. Company Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. United Imaging Healthcare Co., Ltd.
8.4.9.1. Company Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Positron
8.4.10.1. Company Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Modality
1.2.2. Application
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Modality Outlook
2.2.2. Application Outlook
2.2.3. End Use Outlook
2.2.4. Regional Outlook
2.3. Competitive Insights
CHAPTER 3. MOLECULAR IMAGING MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Molecular Imaging Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
CHAPTER 4. MOLECULAR IMAGING MARKET: MODALITY ESTIMATES & TREND ANALYSIS
4.1. Modality Segment Dashboard
4.2. Molecular Imaging Market: Modality Movement Analysis
4.3. Global Molecular Imaging Market Size & Trend Analysis, by Modality, 2018 to 2030 (USD Million)
4.4. Molecular Ultrasound Imaging
4.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.5. Positron Emission Tomography (PET)
4.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.6. Single Photon Emission Computed Tomography (SPECT)
4.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.7. Nuclear Magnetic Resonance (NMR) Spectrometer
4.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. MOLECULAR IMAGING MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Application Segment Dashboard
5.2. Molecular Imaging Market: Application Movement Analysis
5.3. Global Molecular Imaging Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Cardiovascular
5.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.5. Neurology
5.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.6. Oncology
5.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.7. Respiratory
5.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.8. Gastrointestinal
5.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. MOLECULAR IMAGING MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. End Use Segment Dashboard
6.2. Molecular Imaging Market: End Use Movement Analysis
6.3. Global Molecular Imaging Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
6.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5. Diagnostic Imaging Centers
6.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6. Research Institutes
6.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 7. MOLECULAR IMAGING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Molecular Imaging Market by Region: Key Takeaways
7.4. North America
7.4.1. U.S.
7.4.1.1. Key Country Dynamics
7.4.1.2. Regulatory Framework/ Reimbursement Structure
7.4.1.3. Competitive Scenario
7.4.1.4. U.S. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.4.2. Canada
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework/ Reimbursement Structure
7.4.2.3. Competitive Scenario
7.4.2.4. Canada Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.4.3. Mexico
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework/ Reimbursement Structure
7.4.3.3. Competitive Scenario
7.4.3.4. Mexico Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. U.K.
7.5.1.1. Key Country Dynamics
7.5.1.2. Regulatory Framework/ Reimbursement Structure
7.5.1.3. Competitive Scenario
7.5.1.4. U.K. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework/ Reimbursement Structure
7.5.2.3. Competitive Scenario
7.5.2.4. Germany Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.3. France
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework/ Reimbursement Structure
7.5.3.3. Competitive Scenario
7.5.3.4. France Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.4. Italy
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework/ Reimbursement Structure
7.5.4.3. Competitive Scenario
7.5.4.4. Italy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.5. Spain
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework/ Reimbursement Structure
7.5.5.3. Competitive Scenario
7.5.5.4. Spain Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.6. Denmark
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework/ Reimbursement Structure
7.5.6.3. Competitive Scenario
7.5.6.4. Denmark Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.7. Sweden
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework/ Reimbursement Structure
7.5.7.3. Competitive Scenario
7.5.7.4. Sweden Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5.8. Norway
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework/ Reimbursement Structure
7.5.8.3. Competitive Scenario
7.5.8.4. Norway Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Regulatory Framework/ Reimbursement Structure
7.6.1.3. Competitive Scenario
7.6.1.4. Japan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework/ Reimbursement Structure
7.6.2.3. Competitive Scenario
7.6.2.4. China Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6.3. India
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework/ Reimbursement Structure
7.6.3.3. Competitive Scenario
7.6.3.4. India Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6.4. Australia
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework/ Reimbursement Structure
7.6.4.3. Competitive Scenario
7.6.4.4. Australia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework/ Reimbursement Structure
7.6.5.3. Competitive Scenario
7.6.5.4. South Korea Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework/ Reimbursement Structure
7.6.6.3. Competitive Scenario
7.6.6.4. Thailand Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework/ Reimbursement Structure
7.7.2.3. Competitive Scenario
7.7.2.4. Brazil Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework/ Reimbursement Structure
7.7.3.3. Competitive Scenario
7.7.3.4. Argentina Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework/ Reimbursement Structure
7.8.2.3. Competitive Scenario
7.8.2.4. South Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework/ Reimbursement Structure
7.8.3.3. Competitive Scenario
7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework/ Reimbursement Structure
7.8.4.3. Competitive Scenario
7.8.4.4. UAE Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework/ Reimbursement Structure
7.8.5.3. Competitive Scenario
7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company/ Competition Categorization
8.3. Vendor Landscape
8.3.1. Key Company Heat Map Analysis, 2024
8.4. Company Profiles
8.4.1. Bruker
8.4.1.1. Company Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. GE HealthCare
8.4.2.1. Company Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Siemens Healthineers AG
8.4.3.1. Company Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Koninklijke Philips N.V.
8.4.4.1. Company Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Canon Medical Systems Corporation
8.4.5.1. Company Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Mediso Ltd.
8.4.6.1. Company Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Cubresa Inc.
8.4.7.1. Company Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Shimadzu Corporation
8.4.8.1. Company Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. United Imaging Healthcare Co., Ltd.
8.4.9.1. Company Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Positron
8.4.10.1. Company Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
